DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity (2017 - 2026)

DiaMedica Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $53.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 36.7% year-over-year to $53.1 million; the TTM figure through Mar 2026 stood at $203.0 million (up 4.36% YoY), while the FY2025 annual figure was $61.4 million, up 32.42% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $53.1 million, down from $61.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $62.0 million in Q2 2023, with the low at $30.2 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $49.3 million (2024), against an average of $47.3 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 80.3% in 2022, then slumped 44.59% in 2025.
• DiaMedica Therapeutics' Liabilities and Shareholders Equity stood at $34.4 million in 2022, then jumped by 57.46% to $54.2 million in 2023, then dropped by 14.43% to $46.3 million in 2024, then surged by 32.42% to $61.4 million in 2025, then declined by 13.51% to $53.1 million in 2026.
• Business Quant data shows DMAC's Liabilities and Shareholders Equity at $53.1 million in Q1 2026, $61.4 million in Q4 2025, and $57.0 million in Q3 2025.